Logo

PTHL

Pheton Holdings Ltd Class A Ordinary Shares

PTHL

Pheton Holdings Ltd Class A Ordinary Shares • NASDAQ
$0.60 ▲ 0.72% (+0.00)
Market Cap $8.61 M
52w High $32.00
52w Low $0.47
Dividend Yield 0%
P/E -12.08
Volume 19.27K
Outstanding Shares 14.26M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $237.708K ▲ $655.532K ▲ $-375.456K ▼ -157.948% ▼ $-0.026 ▼ $-449.632K ▼
Q2-2024 $210.488K ▼ $495.888K ▲ $-285.132K ▼ -135.462% ▼ $-0.02 ▼ $-311.612K ▼
Q4-2023 $361.804K ▲ $484.08K ▲ $-157.618K ▼ -43.564% ▼ $-0.011 ▼ $-209.16K ▼
Q2-2023 $133.394K ▼ $146.714K ▼ $-41.8K ▼ -31.336% ▼ $-0.006 ▼ $-46.093K ▼
Q4-2022 $292.516K $257.404K $12.39K 4.236% $0 $20.806K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $6.16M ▲ $6.723M ▲ $538.551K ▼ $6.185M ▲
Q2-2024 $17.852K ▼ $1.362M ▼ $1.345M ▲ $16.173K ▼
Q4-2023 $217.885K ▲ $1.617M ▲ $1.31M ▲ $306.272K ▼
Q2-2023 $33.494K ▼ $1.449M ▲ $994.558K ▲ $454.451K ▼
Q4-2022 $72.288K $1.402M $845.412K $556.322K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-330.294K $-387.5K $-430.5 $3.356M $5.932M $-387.93K
Q2-2024 $-330.294K ▼ $-387.5K ▼ $-430.5 ▼ $3.356M ▲ $5.932M ▲ $-387.93K ▼
Q4-2023 $-78.809K ▼ $-32.743K ▼ $0 $227.311K ▲ $193.956K ▲ $-16.371K ▼
Q2-2023 $-41.8K ▼ $-15.447K ▼ $0 $-3.36K ▼ $0 ▲ $-15.447K ▼
Q4-2022 $12.39K $43.976K $0 $16.324K $-64.462K $43.98K

Five-Year Company Overview

Income Statement

Income Statement PTHL currently looks like a pre‑commercial or very early‑stage company from an income‑statement perspective. There is effectively no recorded revenue over the last several years, which means the business has not yet demonstrated that its technology can generate meaningful sales. Earnings per share have drifted from slightly positive to modestly negative, suggesting rising costs (likely from development, listing, and corporate work) without offsetting income. In plain terms, this is still a “building mode” business, not an operating one. Future financial performance will depend on how quickly and successfully it can turn its software and home‑health platform into paying customer relationships.

Balance Sheet

Balance Sheet The balance sheet is very light: a small amount of assets and cash, minimal or no debt, and a thin layer of equity. This points to a company that is still quite small in financial scale and likely dependent on outside capital to fund growth. On the positive side, the absence of meaningful debt reduces pressure from interest payments. On the risk side, the limited asset and cash base means the company does not have a large cushion if commercialization takes longer than expected. Ongoing access to new funding will be important.

Cash Flow

Cash Flow The reported cash‑flow figures are essentially flat and not very informative, which often happens with very early‑stage or recently listed companies where historical cash‑flow disclosure is limited or not yet normalized. In economic reality, a pre‑revenue technology company like this is almost certainly consuming cash for salaries, R&D, and corporate expenses. The key questions are how fast cash is being used, how long the current cash can last, and whether additional capital can be raised on reasonable terms. Those answers won’t be visible from this summary data alone and would require up‑to‑date filings.

Competitive Edge

Competitive Edge Historically, PTHL’s competitive position has centered on a niche: brachytherapy treatment‑planning software for cancer care. Its proprietary planning system and long experience in this narrow field give it some specialist credibility and know‑how, plus a set of related auxiliary products for procedures. However, it competes in a medical‑device and oncology software space that includes much larger, well‑funded players. Its shift toward a broader home‑health technology platform through the iTonic acquisition is a major repositioning. If executed well, this could differentiate the company by combining cancer‑care expertise with home‑based monitoring, medication management, and virtual care. If execution falters, the company risks being “stuck in the middle” between established oncology vendors and larger digital‑health platforms.

Innovation and R&D

Innovation and R&D Innovation is the clear core of PTHL’s story. On the cancer side, it is working on AI‑enabled image recognition to automatically detect tumors and critical organs, plus potential integration with robotic arms to improve precision and standardization in brachytherapy procedures. These are ambitious, high‑impact projects if they can be brought to market and adopted by clinicians. The iTonic acquisition pushes the innovation focus beyond hospitals into the home, combining hardware (like medication dispensing), supply‑chain tools, remote monitoring, and virtual care into a single platform. The R&D challenge now is to integrate these pieces into a coherent, user‑friendly system that meets regulatory standards and gains trust from patients, providers, and payers. Overall, the company is heavy on ideas and development targets, but light on demonstrated commercial traction so far. Execution, regulatory approvals, and clinical and customer acceptance are the main uncertainties.

Summary

PTHL is best viewed as a small, transition‑stage healthcare technology company: historically a niche cancer‑treatment software specialist, now trying to reinvent itself as a broader home‑health and digital‑care platform under the iTonic banner. Financially, it is still pre‑revenue with small but negative earnings, a very lean balance sheet, and likely ongoing cash use. The story is dominated by future potential rather than current financial strength. That creates significant uncertainty: outcomes will depend heavily on management’s ability to integrate the acquisition, commercialize its AI and robotics‑enabled cancer tools, build the home‑health platform, and secure continued funding. In short, this is a high‑innovation, early‑stage profile: rich in technical ambition, but with unproven business scale and meaningful execution and financing risk.

NEWS

October 23, 2025 · 4:15 PM UTC

Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Read more